KYMR

Kymera Therapeutics (KYMR)

Kymera Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:KYMR

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/06/01	21:00	GlobeNewswire Inc.	Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/05/29	20:00	GlobeNewswire Inc.	Kymera Therapeutics to Participate in Upcoming June Investor Conferences	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/05/24	06:00	GlobeNewswire Inc.	Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/05/23	00:20	GlobeNewswire Inc.	Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/05/14	23:00	GlobeNewswire Inc.	Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/05/08	20:00	GlobeNewswire Inc.	Kymera Therapeutics to Participate in Upcoming May Investor Conferences	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/05/02	20:00	GlobeNewswire Inc.	Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/04/25	20:00	GlobeNewswire Inc.	Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/04/08	20:00	GlobeNewswire Inc.	Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/03/09	00:00	GlobeNewswire Inc.	Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/03/05	08:21	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/03/05	08:12	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/03/05	08:12	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/03/05	07:50	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/03/05	07:47	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/02/28	21:00	GlobeNewswire Inc.	Kymera Therapeutics to Participate in Upcoming March Investor Conferences	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/02/28	06:22	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/02/22	21:32	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/02/22	21:10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/02/22	21:00	GlobeNewswire Inc.	Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/02/15	21:00	GlobeNewswire Inc.	Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/02/10	09:47	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/02/10	06:22	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/01/31	21:00	GlobeNewswire Inc.	Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/01/09	23:17	GlobeNewswire Inc.	Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/01/09	23:15	GlobeNewswire Inc.	Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/01/06	06:11	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/01/06	06:02	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/01/05	20:00	GlobeNewswire Inc.	Kymera Therapeutics Announces Pricing of $275 Million Public Offering	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/01/05	06:06	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:KYMR	Kymera Therapeutics Inc